Schering-Plough has initiated patient enrollment in RED-CABG, the Phase III trial for acadesine, an investigational adenosine regulating agent. Acadesine was licensed from PeriCor Therapeutics, a specialty biopharmaceutical company.
FY2009 Outlook AMDL reaffirms that it is on track with its FY2009 projections and expects to meet its FY2009 financial guidance of estimated gross revenues of $64 –
Cimzia can be dosed at 400 mg initially and at weeks two and four, followed by 200 mg every other week; for maintenance dosing, 400 mg every four
Financial Results Total revenue for the first nine months of fiscal 2009 was CAD4.8 million against CAD5.5 million for the first nine months of fiscal 2008. The majority
Osmetech has submitted a request to the FDA for emergency use authorization for its respiratory pathogen test panel test to be used to screen for the swine flu
Nerviano Medical Sciences, an Italian pharmaceutical R&D facility, has received FDA approval for its investigational new drug application to begin a Phase I clinical study with the company’s
Quest Diagnostics, a provider of diagnostic testing, information and services, has reported that its Focus Diagnostics infectious disease reference laboratory has introduced a laboratory-developed real-time polymerase chain reaction
US-based pharmaceutical company Dara BioSciences has reported positive results from a Phase IIa clinical trial of KRN5500 for treatment of neuropathic pain in patients with advanced cancer. KRN5500
Targacept, a biopharmaceutical company, has reported preliminary results showing that AZD3480 met the primary outcome measure in a Phase II clinical study in adults with attention deficit hyperactivity
St Jude Medical, a medical device company, has announced the European CE Mark approval and first use of its EnSite Velocity cardiac mapping system. The EnSite Velocity System
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.